Fulcrum Therapeutics (FULC) Common Equity (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Common Equity data on file, last reported at $333.3 million in Q1 2026.

• On a quarterly basis, Common Equity rose 45.87% year-over-year to $333.3 million in Q1 2026; TTM through Mar 2026 was $333.3 million, a 45.87% increase from a year earlier, with the FY2025 full-year figure at $349.0 million, up 43.6% from the prior year.
• Common Equity for Q1 2026 stood at $333.3 million, down from $349.0 million in the prior quarter.
• Over the last five years, Common Equity for FULC reached as high as $349.0 million in Q4 2025 and fell as low as $160.8 million in Q2 2022.
• Historically, Common Equity has averaged $243.8 million across 5 years, with a median of $235.2 million in 2023.
• Across the five-year window, Common Equity jumped 71.33% in 2023 and fell 27.9% in 2024, its largest moves.
• Year by year, Common Equity stood at $198.9 million in 2022, then gained by 18.22% to $235.2 million in 2023, then increased by 3.33% to $243.0 million in 2024, then soared by 43.6% to $349.0 million in 2025, then dropped by 4.5% to $333.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $333.3 million in Q1 2026, $349.0 million in Q4 2025, and $198.4 million in Q3 2025.